A Phase II Trial of Adjuvant Radiotherapy Combined With Chemotherapy for Patients With High-risk Endometrial Cancer
This phase II clinical trial was designed to assess the feasibility, safety, toxicity, recurrence and survival pattern when TP or CAP chemotherapy was combined with adjuvant radiation for patients with high-risk endometrial cancer.
Prosthesis Survival
RADIATION: radiotherapy|DRUG: Cisplatin|DRUG: Cisplatin and Doxorubicin and Cyclophosphamide|DRUG: Paclitaxel and Carboplatin
Disease Free Survival(DFS), From date of randomization until the date of first documented progression, assessed up to 60 months., From date of randomization until the date of first documented progression, assedded up to 60 months
Overall Survival (OS), From date of randomization until the date of death from any cause, assessed up to 60 months., From date of randomization until the date of death from any cause, assedded up to 60 months.
Number of patients with adverse events and number of patients completed the treatments, Number of patients completed the treatment and number of patients with adverse events up to 5 years., up to 5 years
This phase II clinical trial was designed to assess the feasibility, safety, toxicity, recurrence and survival pattern when TP or CAP chemotherapy was combined with adjuvant radiation for patients with high-risk endometrial cancer.